Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report

Although the incidence of hematological toxicity due to Trifluridine/tipiracil (FTD/TPI) treatment is high, the incidence of severe adverse events has been reported to be relatively low. However, it should be noted that patients with renal impairment are prone to severe hematological adverse events.

Detalles Bibliográficos
Autores principales: Shibutani, Masatsune, Okazaki, Yuki, Kashiwagi, Shinichiro, Nagahara, Hisashi, Fukuoka, Tatsunari, Iseki, Yasuhito, Maeda, Kiyoshi, Hirakawa, Kosei, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894575/
https://www.ncbi.nlm.nih.gov/pubmed/35280098
http://dx.doi.org/10.1002/ccr3.5544
Descripción
Sumario:Although the incidence of hematological toxicity due to Trifluridine/tipiracil (FTD/TPI) treatment is high, the incidence of severe adverse events has been reported to be relatively low. However, it should be noted that patients with renal impairment are prone to severe hematological adverse events.

Ejemplares similares